4.5 Interaction with other medicinal products and other forms of interaction  
 No formal assessments of pharma cokinetic interactions between arsenic trioxide and other therapeutic medicinal products have been conducted.  
 Medicinal products known to cause QT/QTc interval prolongation, hypokalemia or hypomagnesaemia  QT/QTc prolongation is expected during treatment with arsenic trioxide, and torsade de pointes an d complete heart block have been reported. Patients who are receiving, or who have received, medicinal products known to cause hypokalemia or hypomagnesaemia, such as diuretics or amphotericin B, may be at higher risk for torsade de pointes. Caution is adv ised when Arsenic trioxide Mylan  is coadministered with other medicinal products known to cause QT/QTc interval prolongation such as macrolide antibiotics, the antipsychotic thioridazine, or medicinal products known to cause hypokalemia or hypomagnesaemia.  Additional information about QT prolonging medicinal agents, is provided in section 4.4.   
  
7 Medicinal products known to cause hepatotoxic effects  Hepatotoxic effects may occur during the treatment with arsenic trioxide, caution is advised when Arsenic tr ioxide Mylan  is coadministered with other medicinal products known to cause hepatotoxic effects (see section 4.4 and 4.8).  
 Other antileukaemic medicinal products  The influence of Arsenic trioxide Mylan  on the efficacy of other antileukaemic medicinal pr oducts is unknown.  
 
